Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

PHASE3TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

December 14, 2022

Primary Completion Date

August 31, 2023

Study Completion Date

August 31, 2023

Conditions
NSCLC
Interventions
DRUG

Aumolertinib monotherapy

Administered orally, once daily as two 55-mg tablets for a total dose of 110 mg.

DRUG

Osimertinib monotherapy

80 mg tablet administered orally, once daily

DRUG

Pemetrexed

Administered by IV Infusion per prescribing information. Maybe be continued as maintenance therapy

DRUG

Cisplatin

Administered by IV Infusion given over 4 fixed cycles (q3wk × 4 cycles) per prescribing information.

DRUG

Carboplatin

Administered by IV Infusion given over 4 fixed cycles (q3wk × 4 cycles) per prescribing information.

DRUG

Paclitaxel

Administered by IV Infusion given over 4 -6 fixed cycles per prescribing information.

DRUG

Nab paclitaxel

Administered by IV Infusion given over 4 fixed cycles per prescribing information.

DRUG

Gemcitabine

Administered by IV Infusion over 4 fixed cycles per prescribing information.

Trial Locations (8)

33021

Memorial Cancer Institute, Hollywood

33028

Memorial Cancer Institute, Pembroke Pines

37203

SCRI - Tennessee Oncology- Nashville, Nashville

37404

SCRI - Tennessee Oncology PLLC- Chattanooga, Chattanooga

50314

QCCA - Mission Blood & Cancer, Des Moines

72762

Highlands Oncology Group, Springdale

98405

Northwest Medical Specialties, PLLC, Tacoma

07932

Summit Health, Florham Park

Sponsors
All Listed Sponsors
lead

EQRx International, Inc.

INDUSTRY